INLYTA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug INLYTA contains one active pharmaceutical ingredient (API):

1	Axitinib UNII C9LVQ0YUXG - AXITINIB
	Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival.
	Read more about Axitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INLYTA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
INLYTA	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EK01	Axitinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10539Q, 10540R, 10556N, 10572K
BR	Câmara de Regulação do Mercado de Medicamentos	522720020083617, 522720020083717
CA	Health Products and Food Branch	02389630, 02389649
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H5250513
EE	Ravimiamet	1593301, 1593312, 1593323, 1593334, 1593345, 1593356, 1623967, 1623978, 1623989, 1623990, 1624003, 1624014
ES	Centro de información online de medicamentos de la AEMPS	12777002, 12777005
FI	Lääkealan turvallisuus- ja kehittämiskeskus	103854, 599010
FR	Base de données publique des médicaments	61357910, 64922489, 67939209, 69083347
GB	Medicines & Healthcare Products Regulatory Agency	215059, 215062, 245079, 245082, 392402
HK	Department of Health Drug Office	62088, 62089
IE	Health Products Regulatory Authority	88116, 88117
IL	מִשְׂרַד הַבְּרִיאוּת	7169, 7321
IT	Agenzia del Farmaco	042233015, 042233027, 042233039, 042233041, 042233054, 042233066, 042233078, 042233080, 042233092, 042233104, 042233116, 042233128
JP	医薬品医療機器総合機構	4291027F1029, 4291027F2025
LT	Valstybinė vaistų kontrolės tarnyba	1067711, 1067712, 1067713, 1067714, 1067715, 1067716, 1075260, 1075261, 1075262, 1075263, 1075264, 1075265
NL	Z-Index G-Standaard, PRK	104442, 104450, 114650
NZ	Medicines and Medical Devices Safety Authority	15630, 15631
PL	Rejestru Produktów Leczniczych	100084494, 100208499, 100285070, 100285086
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64813001, W64813002, W64813003, W64814001, W64814002, W64814003
SG	Health Sciences Authority	14321P, 14322P
TN	Direction de la Pharmacie et du Médicament	15833011H, 15833012H, 15833013H, 15833014H
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308099181, 8681308099198, 8681308099204, 8681308099211, 8681308099228, 8681308099235, 8681308099754, 8681308099761
US	FDA, National Drug Code	0069-0145, 0069-0151, 63539-026, 63539-044